CCR2 antagonists (Millennium/Pfizer/Kyowa)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCCR2 antagonists (Millennium/Pfizer/Kyowa)
Drug Alias NameCCR2 antagonists (LeukoSite/Warner-Lambert)chemokine blockers (LeukoSite/Warner)inflammation therapeutics (Millennium/Warner)anti-CCR2 mAb (Millennium)CCR2 antagonists (Millennium/Warner-Lambert) +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionC-C chemokine receptor type 2 antagonists
TargetsC-C chemokine receptor type 2
Therapy Area/IndicationsInflammationAutoimmune DiseasesCoronary Restenosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLeukosite
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWarner LambertLeukositePfizer Inc +[5] 
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune DiseasesCoronary Restenosis

Other Information

ATC CodeN/A
Related LinksN/A